The COVID-19 crisis has convulsed global stock markets in a way that had not been seen for a long time. Meanwhile, the search for an effective antiviral treatment has become an almost obsessive global issue where multiple biotech companies are immersed. The main target: to stop the harmful virus with an effective drug and without adverse side effects.
In this race towards find the treatment, at least 30 companies are involved with different types of drugs and in different phases of clinical trials.
Of all these companies, there are about 3 or 4 that are